XML 50 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Related Party Transactions (Narrative) (Details)
3 Months Ended 9 Months Ended
Aug. 05, 2020
USD ($)
Aug. 01, 2020
Dec. 30, 2019
USD ($)
Dec. 27, 2019
USD ($)
director
day
shares
Jun. 04, 2019
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Related Party Transaction [Line Items]                    
Proceeds from related party debt financing               $ 200,000,000 $ 113,700,000  
Amounts due to related parties           $ 628,000   $ 628,000   $ 0
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                    
Related Party Transaction [Line Items]                    
Number of shares owned (in shares) | shares       45,008,604   48,641,181   48,641,181    
Ownership percentage       50.20%   53.50%   53.50%    
Ownership threshold for appointment of directors       50.00%            
Number of independent directors required for audit committee | director       3            
Ownership threshold for voting rights       60.00%            
Ownership threshold for right of ownership percentage maintenance       50.00%            
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder | Sumitovant Consulting Agreement                    
Related Party Transaction [Line Items]                    
Expenses incurred under agreements           $ 200,000   $ 500,000    
Amounts due to related parties           100,000   100,000    
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder | Sunovion Pharmaceuticals Inc. Market Access Services Agreement                    
Related Party Transaction [Line Items]                    
Expenses incurred under agreements           1,400,000   2,500,000    
Amounts due to related parties           600,000   600,000    
Agreement term   3 years                
Agreement extension term   1 year                
Termination notice period   9 months                
Roivant Sciences, Ltd. | Majority Shareholder | Service Agreement                    
Related Party Transaction [Line Items]                    
Expenses incurred under agreements             $ 200,000   600,000  
Roivant Sciences, Ltd. | Majority Shareholder | Share-based Compensation, Expense Allocated to Company                    
Related Party Transaction [Line Items]                    
Expenses incurred under agreements           0 100,000 0 200,000  
Public Offering                    
Related Party Transaction [Line Items]                    
Number of shares issued (in shares) | shares         17,424,243          
Price of shares (in USD per share) | $ / shares         $ 8.25          
Net proceeds from sale of shares         $ 134,500,000          
Public Offering | Roivant Sciences, Ltd. | Majority Shareholder                    
Related Party Transaction [Line Items]                    
Number of shares issued (in shares) | shares         2,424,242          
Price of shares (in USD per share) | $ / shares         $ 8.25          
Net proceeds from sale of shares         $ 20,000,000.0          
Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd.                    
Related Party Transaction [Line Items]                    
Proceeds from related party debt financing     $ 113,700,000              
Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                    
Related Party Transaction [Line Items]                    
Maximum borrowing commitment       $ 400,000,000.0            
Facility term       5 years            
Notice period for prepayment | day       10            
Default interest rate       5.00%            
Repayment period upon change in control       30 days            
Outstanding balance           313,700,000   313,700,000    
Available borrowing capacity           86,300,000   86,300,000    
Interest expense           $ 2,600,000 $ 100,000 $ 6,900,000 $ 100,000  
Term Loan | New Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                    
Related Party Transaction [Line Items]                    
Maximum borrowing commitment $ 200,000,000.0                  
Facility term 5 years                  
LIBOR | Term Loan | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder                    
Related Party Transaction [Line Items]                    
Variable interest rate       3.00%